

Nash Sarah E
Form 4
April 05, 2012

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Nash Sarah E

(Last) (First) (Middle)

C/O MERRIMACK
PHARMACEUTICALS, INC., ONE
KENDALL SQUARE, SUITE
B7201

(Street)

CAMBRIDGE, MA 02139

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
MERRIMACK
PHARMACEUTICALS INC
[MACK]

3. Date of Earliest Transaction
(Month/Day/Year)
04/03/2012

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/03/2012		C		120,161	A	<u>(1)</u> 186,821
Common Stock	04/03/2012		C		28,571	A	<u>(2)</u> 215,392
Common Stock	04/03/2012		C		222,222	A	<u>(3)</u> 437,614
Common Stock	04/03/2012		C		136,058	A	<u>(4)</u> 573,672

Edgar Filing: Nash Sarah E - Form 4

Stock								
Common Stock	04/03/2012	C	25,000	A	(5)	598,672	D	
Common Stock	04/03/2012	C	30,040	A	(1)	628,712	I	By Husband
Common Stock	04/03/2012	C	14,286	A	(2)	642,998	I	By Husband
Common Stock	04/03/2012	C	188,889	A	(3)	831,887	I	By Husband
Common Stock	04/03/2012	C	19,607	A	(4)	851,494	I	By Husband
Common Stock	04/03/2012	C	7,000	A	(5)	858,494	I	By Husband
Common Stock	04/03/2012	C	64,448	A	(4)	922,942	I	By Trust
Common Stock	04/03/2012	C	6,552	A	(4)	929,494	I	By Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Series C Convertible Preferred Stock	(1)	04/03/2012		C	120,161	(1) (1)	Common Stock 120,161
Series D Convertible Preferred Stock	(2)	04/03/2012		C	28,571	(2) (2)	Common Stock 28,571
	(3)	04/03/2012		C	222,222	(3) (3)	222,222

Edgar Filing: Nash Sarah E - Form 4

Series E
Convertible
Preferred
Stock

Common
Stock

Series F
Convertible
Preferred
Stock

(4)

04/03/2012

C

136,058

(4)

(4)

Common
Stock

136,058

Series G
Convertible
Preferred
Stock

(5)

04/03/2012

C

25,000

(5)

(5)

Common
Stock

25,000

Series C
Convertible
Preferred
Stock

(1)

04/03/2012

C

30,040

(1)

(1)

Common
Stock

30,040

Series D
Convertible
Preferred
Stock

(2)

04/03/2012

C

14,286

(2)

(2)

Common
Stock

14,286

Series E
Convertible
Preferred
Stock

(3)

04/03/2012

C

188,889

(3)

(3)

Common
Stock

188,889

Series F
Convertible
Preferred
Stock

(4)

04/03/2012

C

19,607

(4)

(4)

Common
Stock

19,607

Series G
Convertible
Preferred
Stock

(5)

04/03/2012

C

7,000

(5)

(5)

Common
Stock

7,000

Series F
Convertible
Preferred
Stock

(4)

04/03/2012

C

64,448

(4)

(4)

Common
Stock

64,448

Series F
Convertible
Preferred
Stock

(4)

04/03/2012

C

6,552

(4)

(4)

Common
Stock

6,552

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Nash Sarah E
C/O MERRIMACK PHARMACEUTICALS, INC.
ONE KENDALL SQUARE, SUITE B7201
CAMBRIDGE, MA 02139

X

Signatures

/s/ Jeffrey A. Munsie,
attorney-in-fact

04/05/2012

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each share of Series C Convertible Preferred Stock automatically converted into one share of Common Stock upon the closing of the issuer's initial public offering and had no expiration date.
- (2) Each share of Series D Convertible Preferred Stock automatically converted into one share of Common Stock upon the closing of the issuer's initial public offering and had no expiration date.
- (3) Each share of Series E Convertible Preferred Stock automatically converted into one share of Common Stock upon the closing of the issuer's initial public offering and had no expiration date.
- (4) Each share of Series F Convertible Preferred Stock automatically converted into one share of Common Stock upon the closing of the issuer's initial public offering and had no expiration date.
- (5) Each share of Series G Convertible Preferred Stock automatically converted into one share of Common Stock upon the closing of the issuer's initial public offering and had no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.